Neuraxis, Inc. (NRXS)

Price$7.22

Favorite Metrics

Price vs S&P 500 (26W)133.53%

Price vs S&P 500 (4W)-14.74%

Market Capitalization$80.77M

All Metrics

Book Value / Share (Quarterly)$0.32

P/TBV (Annual)15.48x

Revenue Growth (3Y)10.02%

Cash Flow / Share (Quarterly)$-0.62

Price vs S&P 500 (YTD)54.89%

Gross Margin (TTM)84.22%

Net Profit Margin (TTM)-218.55%

EPS (TTM)$-0.88

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-0.88

Revenue Growth (5Y)13.08%

EPS (Annual)$-0.86

ROI (Annual)-219.88%

Gross Margin (Annual)84.23%

Net Profit Margin (5Y Avg)-281.94%

Cash / Share (Quarterly)$0.47

Revenue Growth QoQ (YoY)27.19%

ROA (Last FY)-121.81%

Revenue Growth TTM (YoY)32.89%

EBITD / Share (TTM)$-0.84

Operating Margin (TTM)-219.37%

Cash Flow / Share (Annual)$-0.62

P/B Ratio23.76x

P/B Ratio (Quarterly)14.23x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)21.28x

Net Interest Coverage (TTM)-73.85x

ROA (TTM)-139.93%

EPS Incl Extra (Annual)$-0.86

Current Ratio (Annual)2.05x

Quick Ratio (Quarterly)1.85x

3-Month Avg Trading Volume0.32M

52-Week Price Return345.68%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.29

P/S Ratio (Annual)22.63x

Asset Turnover (Annual)0.56x

52-Week High$7.97

Operating Margin (5Y Avg)-228.01%

EPS Excl Extra (Annual)$-0.86

CapEx CAGR (5Y)34.32%

26-Week Price Return142.28%

Quick Ratio (Annual)1.85x

13-Week Price Return52.32%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)2.05x

Enterprise Value$75.958

Revenue / Share Growth (5Y)4.46%

Asset Turnover (TTM)0.64x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)3.73x

Pretax Margin (Annual)-218.55%

Cash / Share (Annual)$0.47

3-Month Return Std Dev74.95%

Gross Margin (5Y Avg)86.06%

Net Income / Employee (TTM)$-0

ROE (Last FY)-229.47%

Net Interest Coverage (Annual)-73.85x

EPS Basic Excl Extra (Annual)$-0.86

Receivables Turnover (TTM)16.21x

Total Debt / Equity (Quarterly)0.04x

EPS Incl Extra (TTM)$-0.88

Receivables Turnover (Annual)16.21x

ROI (TTM)-290.37%

P/S Ratio (TTM)22.63x

Pretax Margin (5Y Avg)-281.94%

Revenue / Share (Annual)$0.39

Tangible BV / Share (Annual)$0.29

Price vs S&P 500 (52W)310.58%

Year-to-Date Return59.03%

5-Day Price Return3.29%

EPS Normalized (Annual)$-0.86

ROA (5Y Avg)-777.50%

Net Profit Margin (Annual)-218.55%

Month-to-Date Return-2.43%

Cash Flow / Share (TTM)$-2.00

EBITD / Share (Annual)$-0.84

Operating Margin (Annual)-219.37%

LT Debt / Equity (Annual)0.00x

EPS Basic Excl Extra (TTM)$-0.88

P/TBV (Quarterly)15.48x

P/B Ratio (Annual)14.23x

Inventory Turnover (TTM)3.74x

Pretax Margin (TTM)-218.55%

Book Value / Share (Annual)$0.32

Price vs S&P 500 (13W)49.46%

Beta1.57x

Revenue / Share (TTM)$0.34

ROE (TTM)-306.02%

52-Week Low$1.33

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.13

Industry Peers — Electromedical Equipment(29)

Symbol	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
NRXSNeuraxis, Inc.	22.63x	13.08%	84.22%	-219.37%	$7.22
MDTMedtronic plc	3.12x	3.01%	65.16%	17.00%	$86.19
MASIMasimo Corporation	6.12x	5.95%	61.90%	20.30%	$178.39
TMDXTransMedics Group, Inc. Common Stock	6.56x	88.21%	59.92%	17.93%	$115.87
LIVNLivaNova PLC Ordinary Shares	2.64x	8.24%	68.04%	14.09%	$67.12
ITGRInteger Holdings Corporation	1.67x	11.55%	27.39%	11.90%	$90.20
AXGNAxogen, Inc. Common Stock	8.87x	14.93%	74.31%	-3.49%	$38.50
CNMDCONMED Corporation	0.88x	9.77%	54.59%	7.46%	$39.08
BLFSBioLife Solutions Inc.	10.79x	14.87%	64.56%	-17.26%	$21.50
INMDInMode Ltd. Ordinary Shares	2.51x	12.45%	78.54%	23.05%	$14.65
CBLLCeriBell, Inc. Common Stock	8.77x	—	87.89%	-65.57%	$21.19

About

Neuraxis Inc is a growth-stage company developing neuromodulation therapies for chronic and debilitating conditions in children and adolescents. The company's proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology targets disorders of gut-brain interaction (DGBIs) in the pediatric population.